Kylo-12 vs Olezarsen
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Hypertriglyceridemia
Shared mechanism: APOC3 · full Hypertriglyceridemia pipeline
Kylo-12
Developed by Sino Biopharmaceutical and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Olezarsen · Tryngolza
Marketed by Ionis Pharmaceuticals and partners
NCT05610280 · Phase 3 · completed
Essence-TIMI 73b was a large, randomized, double-blind, placebo-controlled trial in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, or with severe hypertriglyceridemia. The primary outcome was the placebo-adjusted percent change in triglycerides from baseline to 6 months in the moderate-hypertriglyceridemia population (1,349 patients). Triglycerides fell by 58.4 percentage points more than placebo with olezarsen 50 mg and by 60.6 percentage points more with 80 mg (P<0.001 for both), so the primary endpoint was met at both doses. The figures come from the peer-reviewed paper (N Engl J Med 2025).
Next expected readout: March 2027 · NCT05681351 (registry estimate)
Reported efficacy
Percent Change from Baseline in Fasting TG Compared to Placebo (Baseline and Month 6): Percent change in fasting triglycerides from baseline vs placebo at Month 6 (CORE2-TIMI 72b, n=444): olezarsen 50 mg -49.2% (95% CI -59.7 to -38.8, p<0.001); olezarsen 80 mg -54.5% (95% CI -65.1 to -44, p<0.001) (met)
Result source: NCT05552326
Results for Hypertriglyceridemia
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Kylo-12: no structured comparison results are available for Hypertriglyceridemia.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Olezarsen
show 7 more results
show 7 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 3 more results
+ 1 further endpoint in the CSV export.
Available safety results
Olezarsen
| Dropout rate | 8.8%80 mg NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results12.1%50 mg NCT05355402 · Phase 2 · registry result, not featured evidence 0%50 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 13%15 mg Q2W NCT03385239 · Phase 2 · registry result, not featured evidence 13.6%10 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 17.4%10 mg QW NCT03385239 · Phase 2 · registry result, not featured evidence |
|---|---|
| Discontinued due to AEs | —80 mg NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results—50 mg NCT05355402 · Phase 2 · registry result, not featured evidence 0%50 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 4.3%15 mg Q2W NCT03385239 · Phase 2 · registry result, not featured evidence 0%10 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 0%10 mg QW NCT03385239 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 14%80 mg NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results10.3%50 mg NCT05355402 · Phase 2 · registry result, not featured evidence 13.6%50 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 17.4%15 mg Q2W NCT03385239 · Phase 2 · registry result, not featured evidence 13.6%10 mg Q4W NCT03385239 · Phase 2 · registry result, not featured evidence 4.3%10 mg QW NCT03385239 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 80 mg covid-19 7% (placebo 5.1%) diabetes mellitus 7% (placebo 2.6%) acute sinusitis 5.3% (placebo 2.6%) NCT05355402 · Phase 2 · registry result, not featured evidence show 5 more results50 mg injection site erythema 13.8% (placebo 0%) fatigue 10.3% (placebo 2.6%) urinary tract infection 10.3% (placebo 15.4%) NCT05355402 · Phase 2 · registry result, not featured evidence 50 mg Q4W injection site erythema 18.2% (placebo 0%) nasopharyngitis 18.2% (placebo 12.5%) nausea 18.2% (placebo 4.2%) NCT03385239 · Phase 2 · registry result, not featured evidence 15 mg Q2W nasopharyngitis 17.4% (placebo 12.5%) arthralgia 13% (placebo 0%) dizziness 13% (placebo 0%) NCT03385239 · Phase 2 · registry result, not featured evidence 10 mg Q4W anaemia 13.6% (placebo 0%) arthralgia 13.6% (placebo 0%) back pain 13.6% (placebo 4.2%) NCT03385239 · Phase 2 · registry result, not featured evidence 10 mg QW injection site erythema 21.7% (placebo 0%) nasopharyngitis 21.7% (placebo 12.5%) upper respiratory tract infection 17.4% (placebo 12.5%) NCT03385239 · Phase 2 · registry result, not featured evidence |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Kylo-12's landscape · Olezarsen's landscape